Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of proximod tablets in moderate-to-severe active rheumatoid arthritis with inadequate response or intolerance to csDMARDs
CTR20242329Phase 2Active
- Sponsor
- Beijing Union Pharmaceutical Factory No. 2
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of proximod in rheumatoid arthritis (RA), sponsored by Beijing Union Pharmaceutical Factory No. 2. Started Sep 2024; status: active.
02
Drugs
proximod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20242329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242329.